

2024. Thiopurine withdrawal

RCT/Thiopurine withdrawal/ UC/

Multicentre, randomized controlled trial. Patients with UC on vedolizumab 300mg q8w and a thiopurine in steroid-free clinical remission for over 6 months and endoscopic remission/improvement were randomized to withdraw or continue thiopurine.

Primary endpoint: Week 48 vedolizumab trough concentrations.

Results: N=62

- At w48 trough concentrations of VEDO were not different between groups.
- VEDO+thiopurine group had higher FC remission 95% vs 71.4%, $p=0.03$
- VEDO+thiopurine group had higher histologic and histo-endoscopic remission than withdrawal group.
- Histological activity and prior antiTNF predicted clinical relapse after thiopurine withdrawal.

Conclusion:

Thiopurine withdrawal did not affect vedolizumab trough concentrations. However, it may increase fecal calprotectin, histologic and histo-endoscopic activity.

Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial

